Danino T, Prindle A, Kwong GA, et al. Programmable probiotics for detection of cancer in urine. Sci Transl Med. 2015;7(289):289ra84. doi:10.1126/scitranslmed.aaa3519
Zhang CZ, Spektor A, Cornils H, et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015;522(7555):179-84. doi:10.1038/nature14493
Jiang P, Freedman ML, Liu JS, Liu XS. Inference of transcriptional regulation in cancers. Proc Natl Acad Sci U S A. 2015;112(25):7731-6. doi:10.1073/pnas.1424272112
Adams DJ, Ito D, Rees MG, et al. NAMPT is the cellular target of STF-31-like small-molecule probes. ACS Chem Biol. 2014;9(10):2247-54. doi:10.1021/cb500347p
Boehm JS, Golub TR. An ecosystem of cancer cell line factories to support a cancer dependency map. Nat Rev Genet. 2015;16(7):373-4. doi:10.1038/nrg3967
Kwiatkowski DJ, Wagle N. mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses? EBioMedicine. 2015;2(1):2-4. doi:10.1016/j.ebiom.2014.12.011
Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO. The extracellular matrix: Tools and insights for the "omics" era. Matrix Biol. 2016;49:10-24. doi:10.1016/j.matbio.2015.06.003
Laughney AM, Elizalde S, Genovese G, Bakhoum SF. Dynamics of Tumor Heterogeneity Derived from Clonal Karyotypic Evolution. Cell Rep. 2015;12(5):809-20. doi:10.1016/j.celrep.2015.06.065
Chan K, Roberts SA, Klimczak LJ, et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet. 2015;47(9):1067-72. doi:10.1038/ng.3378
Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL. Identification of an oncogenic RAB protein. Science. 2015;350(6257):211-7. doi:10.1126/science.aaa4903